Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Other Non-Current Assets: 2020-2024

Historic Other Non-Current Assets for Autolus Therapeutics (AUTL) over the last 5 years, with Dec 2024 value amounting to $963,000.

  • Autolus Therapeutics' Other Non-Current Assets fell 0.19% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 0.19%. This contributed to the annual value of $963,000 for FY2024, which is 2.03% down from last year.
  • Latest data reveals that Autolus Therapeutics reported Other Non-Current Assets of $963,000 as of FY2024, which was down 2.03% from $983,000 recorded in FY2023.
  • Autolus Therapeutics' Other Non-Current Assets' 5-year high stood at $3.0 million during FY2020, with a 5-year trough of $963,000 in FY2024.
  • Moreover, its 3-year median value for Other Non-Current Assets was $983,000 (2023), whereas its average is $1.4 million.
  • Data for Autolus Therapeutics' Other Non-Current Assets shows a maximum YoY plummeted of 54.83% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Autolus Therapeutics' Other Non-Current Assets stood at $3.0 million in 2020, then decreased by 22.12% to $2.4 million in 2021, then fell by 7.87% to $2.2 million in 2022, then tumbled by 54.83% to $983,000 in 2023, then dropped by 2.03% to $963,000 in 2024.